Neuroharmonics

Neurotech platform using ultrasound technology to non-invasively treat and interface with the brain.

Woman sits under machine that wraps around her head while clinician stands next to her looking at computer

Neuroharmonics is built on a decade of the founders' research in biomedical ultrasound.

Noticing the inability to precisely target deep brain structures without invasive surgery, the company has designed and built a new platform to focus low-intensity ultrasound through the skull to influence brain circuits, guided by an MRI scan and computational models. The stimulation is non-ablative (it does not destroy tissue), and is built to be repeatable.

Ultrasound shows promise for treating neurological and psychiatric conditions, as well as a foundation for next-generation neuromodulation applications.

Once approved outside of the clinic, sessions are intended for an ordinary outpatient setting: no surgery, no implant, no anaesthesia and no head shaving. 

The Neuroharmonics journey so far: 

  • 2024: the company spun out of UCL.

Team

Dr Brad Treeby

Dr Brad Treeby

Co-founder and CEO

Dr Treeby has spent the last decade working on how to focus ultrasound through the skull and into the brain to modulate neural activity.

He has helped build k-Wave (an open-source simulation toolbox), designed new transducer arrays, and ran the first human studies demonstrating millimetre-scale targeting of deep brain structures without surgery. He left academia to solve problems like these full time.

Antonio Stanziola

Dr Antonio Stanziola

Co-founder and Chief Technology Officer

Dr Michael Brown, Co-founder and Chief Scientific Officer

Dr Weng Sie Wong

Senior Business Manager

Dr Wong brings extensive experience of all aspects of university technology transfer activities from strategic IP management to licence negotiations and spinout formation.

As a Senior Business Manager focusing on the commercialisation of medical technologies, healthcare engineering, medical imaging and AI-enabled healthcare innovations arising from UCL research, she has been involved in the formation of multiple spinouts and acted as a director on various boards.

Prior to joining UCL Ventures, Dr Wong was a senior technology transfer manager at Oxford University’s TTO, Oxford University Innovation, working on a diverse range of both life and physical science projects over a 10-year period.

Weng holds an MBA from Edinburgh University and a PhD in pharmacology from UCL.